Remdesivir is at the forefront in the fight against the virus after the drug helped shorten hospital recovery times in a clinical trial. Two major Indian drugmakers - Hetero Labs and Cipla Ltd - on Sunday gained approval to begin selling their generic versions of remdesivir in the country. Gilead's expectations of two million courses suggests sales of between $2 billion and $3 billion between 2020 and 2021 at a price of $1,000 to $2,000 per course, according to Jefferies analyst Michael Yee. Gilead had previously said it expected to produce one million courses of remdesivir by 2020. Gilead said an inhaled formulation of the drug would be given through a nebulizer, which could potentially allow for easier use outside hospitals.

Source: bd News24 June 22, 2020 15:11 UTC